Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients

Por: Garcia-Castano, A, Gonzalez-Barrallo, I, Rubio, VEC, Martinez, JM, Mozo, JLM, Mujika, K, Tarruella, MM, de La Rosa, CA, Suarez, MAC, Palacio, I, Osterloh, L and Fernandez, AM

---

Publicada: 1 sep 2020

---

---

Filiaciones:
Garcia-Castano, A:
 Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain

Gonzalez-Barrallo, I:
 Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

Rubio, VEC:
 Hosp Univ Torrecardenas, Med Oncol, Almeria, Spain

Martinez, JM:
 Hosp Virgen de la Salud, Med Oncol, Toledo, Spain

:
 Germans Trias & Pujol Univ Hosp HUGTiP, Badalona Appl Res Grp Oncol B ARGO, Catalan Inst Oncol ICO Badalona, Med Oncol, Badalona, Spain

Mujika, K:
 UGC Oncol Gipuzkoa HU Donostia Onkol, Med Oncol, Donostia San Sebastian, Spain

Tarruella, MM:
 Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

de La Rosa, CA:
 Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain

Suarez, MAC:
 Hosp Univ Nuestra Senora Candelaria, Med Oncol, Santa Cruz De Tenerife, CA, Spain

Palacio, I:
 Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain

Osterloh, L:
 Novartis Farmaceut SA, Med Affairs, Barcelona, Spain

Fernandez, AM:
 Novartis Farmaceut SA, Med Affairs, Barcelona, Spain